ÁÖ»ç Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¾à¹° Á¾·ùº°, Åõ¿© ¹æ¹ýº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Rosacea Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antibiotics, Alpha Agonists, Retinoids, Corticosteroids), By Mode Of Administration (Topical, Oral), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1631518
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÁÖ»ç Ä¡·á ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ÁÖ»ç Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 31¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â ¿¬Æò±Õ 7.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÷´Ü Á¦Á¦ ¹× Áúº´ÀÇ ³ôÀº À¯º´·ü µî ¸î °¡Áö ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î 4¾ï ¸í ÀÌ»óÀÌ ¾Î°í ÀÖÀ¸¸ç, Àü ¼¼°è ¼ºÀÎ ¹ßº´·üÀº 5%·Î ÃßÁ¤µË´Ï´Ù. Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ´Â 150¸¸ ¸í ÀÌÇÏÀ̸ç, Áø´ÜÀÌ ¸Å¿ì ´Ê°Ô ÀÌ·ç¾îÁö´Â ÁúȯÀÔ´Ï´Ù. ÀÌ ÁúȯÀº ³²¼ºº¸´Ù ¿©¼º¿¡¼­ ¹ßº´·üÀÌ ³ôÀ¸¸ç, ÀϺΠ¿¬±¸¿¡¼­´Â À½ÁÖ¿Í °»³â±â Àå¾Ö¿ÍÀÇ ¿¬°ü¼ºÀ» ÁöÀûÇϰí ÀÖ½À´Ï´Ù. Àý´ëÀûÀÎ Ä¡·á¹ýÀÌ È®¸³µÇÁö ¾Ê¾Ò±â ¶§¹®¿¡ Ä¡·áÀÇ ¼±ÅÃÀº Áúº´ °ü¸®¿¡ ÁýÁߵǾî ÀÖ½À´Ï´Ù.

¿©µå¸§ Ä¡·á ½ÃÀåÀº ¿©·¯ ƯÇã ¸¸·á·Î ÀÎÇØ Á¦³×¸¯ ÀǾàǰÀÌ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖÀ¸¸ç, ¸Å¿ì ¼¼ºÐÈ­µÈ Ä¡·á »óȲÀÔ´Ï´Ù. ¿©µå¸§Àº °ú¼Ò Áø´ÜµÇ±â ½¬¿î ÁúȯÀ¸·Î ¿©µå¸§À¸·Î ¿ÀÁøµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Ä¡·áÀÇ ÀûÀÀÁõ ¿Ü »ç¿ëÀº ¿©µå¸§¿¡ ƯȭµÈ Ä¡·á¿¡¼­ Ä¡¿­ÇÑ °æÀïÀ» À¯¹ßÇϰí ÀÖ½À´Ï´Ù.

±¹¼Ò Ä¡·á´Â ¿©ÀüÈ÷ Ä¡·áÀÇ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±¹¼Ò Á¦Ç°Àº 2017³â¿¡ 60% ÀÌ»óÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ±¹¼Ò Á¦Ç°Àº °æ±¸¿ë ÀǾàǰ¿¡ ºñÇØ ¼±µÎ¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, º´¿ë Á¦Ç°¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀåÀº ÆÐ·¯´ÙÀÓÀÇ º¯È­¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù.

ÁÖ»ç Ä¡·á ¿É¼ÇÀ¸·Î´Â Ç×»ýÁ¦, ¾ËÆÄ ÀÛ¿ëÁ¦, ·¹Æ¼³ëÀ̵å, ¸é¿ª¾ïÁ¦Á¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, Ç×°íÇ÷¾ÐÁ¦ µîÀÌ ÀÖ½À´Ï´Ù. Ç×»ýÁ¦´Â Ä¡·áÀÇ Ã¹ ¹øÂ° ¼±Åà ¾àÁ¦·Î¼­ 2017³â¿¡´Â ¾àÁ¦±ºº°·Î Ç×»ýÁ¦°¡ ¿ìÀ§¸¦ Á¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â 2025³â±îÁö Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº Rhofade, Mirvaso, Oracea, MetroGel, Noritate, Finacea µî ÁÖ¿ä Á¦Ç°µéÀÇ »ó¾÷Àû ÆÇ¸Å È£Á¶¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀÇ Ä§Åõ°¡ ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÁö¸¸, À¯¸ÁÇÑ ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°ÀÇ Ãâ½Ã°¡ ÀÓ¹ÚÇÔ¿¡ µû¶ó ¼¼°è ½ÃÀåÀÇ ¹Ì·¡´Â ³«°üÀûÀÔ´Ï´Ù.

ÁÖ»ç Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÁÖ»ç Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÁÖ»ç Ä¡·á ½ÃÀå : ¾à¹° Á¾·ù ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ÁÖ»ç Ä¡·á ½ÃÀå : Åõ¿© ¹æ¹ý ºñÁî´Ï½º ºÐ¼®

Á¦6Àå ÁÖ»ç Ä¡·á ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Rosacea Treatment Market Growth & Trends:

The global rosacea treatment market size is expected to reach USD 3.12 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 7.1% from 2025 to 2030. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

Rosacea Treatments Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Rosacea Treatment Market Variables, Trends, & Scope

Chapter 4. Rosacea Treatment Market: Drug Class Business Analysis

Chapter 5. Rosacea Treatment Market: Mode of Administration Business Analysis

Chapter 6. Rosacea Treatment Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â